

Giovanni Del Poeta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8350708/publications.pdf>

Version: 2024-02-01

158
papers

7,275
citations

57758

44
h-index

64796

79
g-index

159
all docs

159
docs citations

159
times ranked

7135
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. <i>Blood</i> , 2013, 121, 1403-1412.	1.4	420
2	Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). <i>Blood</i> , 2003, 101, 2125-2131.	1.4	309
3	Response to B-cellâ€‘depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. <i>Blood</i> , 2007, 110, 2924-2930.	1.4	267
4	Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. <i>Blood</i> , 2012, 119, 332-341.	1.4	246
5	Clinical significance of CD38 expression in chronic lymphocytic leukemia. <i>Blood</i> , 2001, 98, 2633-2639.	1.4	242
6	Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. <i>Blood</i> , 2008, 111, 865-873.	1.4	226
7	Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. <i>Blood</i> , 2000, 96, 3948-3952.	1.4	225
8	COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. <i>Leukemia</i> , 2020, 34, 2354-2363.	7.2	198
9	Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia. <i>Blood</i> , 2015, 126, 1921-1924.	1.4	197
10	Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. <i>Blood</i> , 2006, 108, 853-861.	1.4	171
11	Toward Optimization of Postremission Therapy for Residual Diseaseâ€‘Positive Patients With Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2008, 26, 4944-4951.	1.6	165
12	CD49d Is the Strongest Flow Cytometryâ€‘Based Predictor of Overall Survival in Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2014, 32, 897-904.	1.6	162
13	CD38/CD31, the CCL3 and CCL4 Chemokines, and CD49d/Vascular Cell Adhesion Molecule-1 Are Interchained by Sequential Events Sustaining Chronic Lymphocytic Leukemia Cell Survival. <i>Cancer Research</i> , 2009, 69, 4001-4009.	0.9	153
14	Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia. <i>Blood</i> , 2010, 116, 2295-2303.	1.4	126
15	The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. <i>Leukemia</i> , 2006, 20, 1783-1789.	7.2	117
16	Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia. <i>Blood</i> , 2013, 121, 4902-4905.	1.4	113
17	Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study. <i>British Journal of Haematology</i> , 2009, 144, 492-506.	2.5	106
18	Chlorambucil plus rituximab with or without maintenance rituximab as firstâ€‘line treatment for elderly chronic lymphocytic leukemia patients. <i>American Journal of Hematology</i> , 2014, 89, 480-486.	4.1	104

#	ARTICLE	IF	CITATIONS
19	Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. <i>Cancer</i> , 2008, 112, 119-128.	4.1	86
20	The CD49d/CD29 complex is physically and functionally associated with CD38 in B-cell chronic lymphocytic leukemia cells. <i>Leukemia</i> , 2012, 26, 1301-1312.	7.2	78
21	Incidence of chromosome abnormalities and clinical significance of karyotype in de novo acute myeloid leukemia. <i>Cancer Genetics and Cytogenetics</i> , 1993, 67, 28-34.	1.0	77
22	The miR-17-1/492 family regulates the response to Toll-like receptor 9 triggering of CLL cells with unmutated IGHV genes. <i>Leukemia</i> , 2012, 26, 1584-1593.	7.2	77
23	Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow. <i>Haematologica</i> , 2007, 92, 605-611.	3.5	76
24	Minimally Differentiated Acute Myeloid Leukemia (AML-M0): Comparison of 25 Cases With Other French-American-British Subtypes. <i>Blood</i> , 1997, 89, 621-629.	1.4	75
25	Comparative study on the immunogenicity between an HLA-A24-restricted cytotoxic T-cell epitope derived from survivin and that from its splice variant survivin-2B in oral cancer patients. <i>Journal of Translational Medicine</i> , 2009, 7, 1.	4.4	74
26	NOTCH1 mutations associate with low CD20 level in chronic lymphocytic leukemia: evidence for a NOTCH1 mutation-driven epigenetic dysregulation. <i>Leukemia</i> , 2016, 30, 182-189.	7.2	74
27	CD49d expression is an independent risk factor of progressive disease in early stage chronic lymphocytic leukemia. <i>Haematologica</i> , 2008, 93, 1575-1579.	3.5	72
28	Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation. <i>Leukemia</i> , 2003, 17, 2178-2182.	7.2	67
29	13q14 Deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2011, 50, 633-643.	2.8	67
30	Deregulation of the Mitochondrial Apoptotic Machinery and Development of Molecular Targeted Drugs in Acute Myeloid Leukemia. <i>Current Cancer Drug Targets</i> , 2008, 8, 207-222.	1.6	66
31	The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia – analysis of 848 patients. <i>Leukemia</i> , 2001, 15, 903-909.	7.2	65
32	Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia. <i>Journal of Experimental Medicine</i> , 2018, 215, 681-697.	8.5	65
33	Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia. <i>Haematologica</i> , 2020, 105, 448-456.	3.5	64
34	Comprehensive characterization of IGHV3-21-expressing B-cell chronic lymphocytic leukemia: an Italian multicenter study. <i>Blood</i> , 2007, 109, 2989-2998.	1.4	62
35	Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. <i>Blood</i> , 2000, 96, 3948-3952.	1.4	60
36	IGHV3-21 is an inherited risk factor for CLL through the acquisition of a single-point mutation enabling autonomous BCR signaling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 4320-4327.	7.1	55

#	ARTICLE	IF	CITATIONS
37	Analysis of IgVH gene mutations in BÂcell chronic lymphocytic leukaemia according to antigen-driven selection identifies subgroups with different prognosis and usage of the canonical somatic hypermutation machinery. British Journal of Haematology, 2004, 126, 29-42.	2.5	54
38	Fulminant B hepatitis in a surface antigen-negative patient with B-cell chronic lymphocytic leukaemia after rituximab therapy. Leukemia, 2005, 19, 1840-1841.	7.2	53
39	Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia. Haematologica, 2016, 101, 77-85.	3.5	53
40	Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia. Blood, 2010, 116, 584-592.	1.4	51
41	CENTRAL NERVOUS SYSTEM INVOLVEMENT IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: DIAGNOSTIC TOOLS, PROPHYLAXIS AND THERAPY. Mediterranean Journal of Hematology and Infectious Diseases, 2014, 6, e2014075.	1.3	50
42	A scoring system based on the expression of six surface molecules allows the identification of three prognostic risk groups in B-cell chronic lymphocytic leukemia. Journal of Cellular Physiology, 2006, 207, 354-363.	4.1	49
43	CD49d is overexpressed by trisomy 12 chronic lymphocytic leukemia cells: evidence for a methylation-dependent regulation mechanism. Blood, 2013, 122, 3317-3321.	1.4	48
44	The coexistence of chronic lymphocytic leukemia and myeloproliferative neoplasms: A retrospective multicentric GIMEMA experience. American Journal of Hematology, 2011, 86, 1007-1012.	4.1	47
45	Minimally differentiated acute myeloid leukaemia (AML-MO): cytochemical, immunophenotypic and cytogenetic analysis of 19 cases. British Journal of Haematology, 1994, 88, 784-793.	2.5	46
46	The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia. Cancer, 2005, 104, 2743-2752.	4.1	45
47	The cumulative amount of serum-free light chain is a strong prognosticator in chronic lymphocytic leukemia. Blood, 2011, 118, 6353-6361.	1.4	45
48	Expression of Mutated <i>IGHV3-23</i> Genes in Chronic Lymphocytic Leukemia Identifies a Disease Subset with Peculiar Clinical and Biological Features. Clinical Cancer Research, 2010, 16, 620-628.	7.0	44
49	A cluster of <i>Geotrichum clavatum</i> (<i>Saprochaete clavata</i>) infection in haematological patients: a first Italian report and review of literature. Mycoses, 2016, 59, 594-601.	4.0	44
50	CD7 Expression in Acute Myeloid Leukemia. Leukemia and Lymphoma, 1995, 17, 111-119.	1.3	43
51	Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia. ELife, 2014, 3, .	6.0	43
52	Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance. Journal of Translational Medicine, 2009, 7, 76.	4.4	41
53	Infections increase the risk of central venous catheter-related thrombosis in adult acute myeloid leukemia. Thrombosis Research, 2013, 132, 511-514.	1.7	41
54	A Comparative Analysis of FISH, RT-PCR, and Cytogenetics for the Diagnosis of <i>bcr-abl</i>Positive Leukemias. American Journal of Clinical Pathology, 1998, 109, 24-31.	0.7	39

#	ARTICLE	IF	CITATIONS
55	Involvement of central nervous system in adult patients with acute myeloid leukemia: Incidence and impact on outcome. <i>Seminars in Hematology</i> , 2018, 55, 209-214.	3.4	39
56	HIF-1 α is over-expressed in leukemic cells from <i>TP53</i> -disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia. <i>Haematologica</i> , 2020, 105, 1042-1054.	3.5	39
57	Intensive treatment of patients age 60 years and older with De novo acute myeloid leukemia: Analysis of prognostic factors. , 1996, 77, 2476-2488.		38
58	ZAP-70 expression in B-cell chronic lymphocytic leukemia: Evaluation by external (isotypic) or internal (T/NK cells) controls and correlation with IgVH mutations. <i>Cytometry Part B - Clinical Cytometry</i> , 2006, 70B, 284-292.	1.5	38
59	NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment. <i>Annals of Hematology</i> , 2014, 93, 1765-1774.	1.8	34
60	P-glycoprotein and terminal transferase expression identify prognostic subsets within cytogenetic risk classes in acute myeloid leukemia. <i>Leukemia Research</i> , 1999, 23, 451-465.	0.8	33
61	Monocytes/macrophages but not T lymphocytes are the major targets of the CCL3/CCL4 chemokines produced by CD38 ⁺ CD49d ⁺ chronic lymphocytic leukaemia cells. <i>British Journal of Haematology</i> , 2010, 150, 111-112.	2.5	33
62	Endothelin-1 Promotes Survival and Chemoresistance in Chronic Lymphocytic Leukemia B Cells through ETA Receptor. <i>PLoS ONE</i> , 2014, 9, e98818.	2.5	33
63	CD49d promotes disease progression in chronic lymphocytic leukemia: new insights from CD49d bimodal expression. <i>Blood</i> , 2020, 135, 1244-1254.	1.4	33
64	FISH analysis for CML monitoring? <i>Annals of Hematology</i> , 1996, 73, 113-119.	1.8	32
65	P-glycoprotein and BCL-2 levels predict outcome in adult acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2003, 121, 730-738.	2.5	32
66	CD69 is independently prognostic in chronic lymphocytic leukemia: a comprehensive clinical and biological profiling study. <i>Haematologica</i> , 2012, 97, 279-287.	3.5	32
67	A shorter time to the first treatment may be predicted by the absolute number of regulatory T cells in patients with Rai stage 0 chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2012, 87, 628-631.	4.1	32
68	Microenvironmental Interactions in Chronic Lymphocytic Leukemia: The Master Role of CD49d. <i>Seminars in Hematology</i> , 2014, 51, 168-176.	3.4	32
69	Chromosomal Aberration of the 11q23 Locus in Acute Leukemia and Frequency of MLL Gene Translocation Results in 378 Adult Patients. <i>American Journal of Clinical Pathology</i> , 2004, 122, 298-306.	0.7	31
70	Signature of B-CLL with different prognosis by Shrunken centroids of surface antigen expression profiling. <i>Journal of Cellular Physiology</i> , 2005, 204, 113-123.	4.1	30
71	B cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: the growing saga of the <i>IGHV3</i> subgroup gene usage. <i>British Journal of Haematology</i> , 2011, 153, 3-14.	2.5	30
72	Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia. <i>Hematological Oncology</i> , 2011, 29, 91-99.	1.7	30

#	ARTICLE	IF	CITATIONS
73	High sensitivity of flow cytometry improves detection of occult leptomeningeal disease in acute lymphoblastic leukemia and lymphoblastic lymphoma. <i>Annals of Hematology</i> , 2014, 93, 1509-1513.	1.8	30
74	Minimal residual disease negativity in elderly patients with acute myeloid leukemia may indicate different postremission strategies than in younger patients. <i>Annals of Hematology</i> , 2015, 94, 1319-1326.	1.8	30
75	P-Glycoprotein Expression in De Novo Acute Myeloid Leukemia. <i>Leukemia and Lymphoma</i> , 1997, 27, 257-274.	1.3	29
76	Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments. <i>Leukemia Research</i> , 2015, 39, 1066-1070.	0.8	29
77	Minimally differentiated acute myeloid leukemia (AML-MO): a distinct clinico-biologic entity with poor prognosis. <i>Annals of Hematology</i> , 1996, 72, 208-215.	1.8	27
78	MDM4 (MDMX) is overexpressed in chronic lymphocytic leukaemia (CLL) and marks a subset of p53 wild-type CLL with a poor cytotoxic response to Nutlin-3. <i>British Journal of Haematology</i> , 2010, 150, 237-239.	2.5	27
79	Comparison between conventional banding analysis and FISH screening with an AML-specific set of probes in 260 patients. <i>The Hematology Journal</i> , 2003, 4, 263-270.	1.4	27
80	CD90/Thy-1 is preferentially expressed on blast cells of high risk acute myeloid leukaemias*. <i>British Journal of Haematology</i> , 2004, 125, 203-212.	2.5	26
81	In vitro down-regulation of bcl-2 expression by all-trans retinoic acid in AML blasts. <i>Annals of Hematology</i> , 1997, 75, 145-147.	1.8	25
82	Clinical heterogeneity of de novo 11q deletion chronic lymphocytic leukaemia: prognostic relevance of extent of 11q deleted nuclei inside leukemic clone. <i>Hematological Oncology</i> , 2013, 31, 88-95.	1.7	25
83	TP53 Mutations with Low Variant Allele Frequency Predict Short Survival in Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2021, 27, 5566-5575.	7.0	23
84	Chronic lymphocytic leukemia-associated immune thrombocytopenia treated with rituximab: a retrospective study of 21 patients. <i>European Journal of Haematology</i> , 2010, 85, 502-507.	2.2	22
85	Potential therapeutic role of antagomiR17 for the treatment of chronic lymphocytic leukemia. <i>Journal of Hematology and Oncology</i> , 2014, 7, 79.	17.0	22
86	Clinical Relevance of Minimal Residual Disease Detection in Adult Acute Myeloid Leukemia. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2002, 11, 349-357.	1.8	21
87	Collection of peripheral progenitor cells: a comparison between Amicus and Cobe-Spectra blood cell separators. <i>Transfusion and Apheresis Science</i> , 2004, 30, 131-136.	1.0	21
88	Normal lymphocytes from leukemic samples as an internal quality control for fluorescence intensity in immunophenotyping of acute leukemias. <i>Cytometry Part B - Clinical Cytometry</i> , 2006, 70B, 1-9.	1.5	21
89	IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia. <i>Journal of Translational Medicine</i> , 2012, 10, 18.	4.4	21
90	Combined analysis of bcl-2 and MDR1 proteins in 256 cases of acute myeloid leukemia. <i>Haematologica</i> , 2004, 89, 934-9.	3.5	20

#	ARTICLE	IF	CITATIONS
91	Apoptosis and immaturity in acute myeloid leukemia. Hematology, 2005, 10, 25-34.	1.5	19
92	Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cells. Journal of Translational Medicine, 2010, 8, 23.	4.4	19
93	MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA OF ADULTS: DETERMINATION, PROGNOSTIC IMPACT AND CLINICAL APPLICATIONS.. Mediterranean Journal of Hematology and Infectious Diseases, 2016, 8, 2016052.	1.3	18
94	Mutations in the 3' untranslated region of <i>NOTCH1</i> are associated with low CD20 expression levels chronic lymphocytic leukemia. Haematologica, 2017, 102, e305-e309.	3.5	18
95	The SIRT1/TP53 axis is activated upon B-cell receptor triggering via miR-132 up-regulation in chronic lymphocytic leukemia cells. Oncotarget, 2015, 6, 19102-19117.	1.8	18
96	Clinical significance of soluble p53 protein in B-cell chronic lymphocytic leukemia. Haematologica, 2004, 89, 1468-75.	3.5	18
97	Surface-antigen expression profiling (SEP) in B-cell chronic lymphocytic leukemia (B-CLL): Identification of markers with prognostic relevance. Journal of Immunological Methods, 2005, 305, 20-32.	1.4	17
98	Immunophenotypic characterization of IgVH3-72 B-cell chronic lymphocytic leukaemia (B-CLL). Leukemia Research, 2006, 30, 1197-1199.	0.8	17
99	Cluster analysis of immunophenotypic data: The example of chronic lymphocytic leukemia. Immunology Letters, 2011, 134, 137-144.	2.5	17
100	Microenvironmental Interactions in Chronic Lymphocytic Leukemia: Hints for Pathogenesis and Identification of Targets for Rational Therapy. Current Pharmaceutical Design, 2012, 18, 3323-3334.	1.9	17
101	Complementary and alternative medicine use in patients with chronic lymphocytic leukemia: an Italian multicentric survey. Leukemia and Lymphoma, 2014, 55, 841-847.	1.3	17
102	Spontaneous apoptosis and proliferation detected by BCL-2 and CD71 proteins are important progression indicators within ZAP-70 negative chronic lymphocytic leukemia. Leukemia and Lymphoma, 2010, 51, 95-106.	1.3	16
103	The genotype nucleophosmin mutated and <i>FLT3</i> negative is characterized by high bax/bcl-2 ratio and favourable outcome in acute myeloid leukaemia. British Journal of Haematology, 2010, 149, 383-387.	2.5	15
104	A laboratory-based scoring system predicts early treatment in Rai O chronic lymphocytic leukemia. Haematologica, 2020, 105, 1613-1620.	3.5	15
105	High-dose chemotherapy in adult acute myeloid leukemia: Rationale and results. Leukemia Research, 1996, 20, 535-549.	0.8	14
106	A microgranular variant of acute promyelocytic leukemia with atypical morpho-cytochemical features and an early myeloid immunophenotype. Leukemia Research, 1997, 21, 575-580.	0.8	14
107	Biological Features of Acute Myeloid Leukemia in the Elderly. Blood, 1998, 92, 697-699.	1.4	14
108	Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes. Haematologica, 2012, 97, 849-853.	3.5	14

#	ARTICLE	IF	CITATIONS
109	Clinical significance of c.7544â€7545 del<scp>CT </scp><i><scp>NOTCH</scp>1</i> mutation in chronic lymphocytic leukaemia. British Journal of Haematology, 2013, 160, 415-418.	2.5	14
110	Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application. Journal of Hematology and Oncology, 2013, 6, 83.	17.0	14
111	New reciprocal translocation t(6;10) (q27;q11) associated with idiopathic myelofibrosis and eosinophilia. Leukemia Research, 2001, 25, 349-351.	0.8	13
112	REGULATORY T-CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA. Mediterranean Journal of Hematology and Infectious Diseases, 2012, 4, e2012053.	1.3	12
113	<i>>SF3B1</i>-mutated chronic lymphocytic leukemia shows evidence of NOTCH1 pathway activation including CD20 downregulation. Haematologica, 2021, 106, 3125-3135.	3.5	12
114	Fluorescence in situ hybridization and conventional cytogenetics for the diagnosis of 11q23+ /mll + translocation in leukaemia. British Journal of Haematology, 2003, 121, 953-955.	2.5	11
115	Multidimensional Flow Cytometry for Detection of Minimal Residual Disease in Acute Myeloid Leukemia. Leukemia and Lymphoma, 2003, 44, 445-450.	1.3	11
116	Mutational status of <i>IGHV</i> is the most reliable prognostic marker in trisomy 12 chronic lymphocytic leukemia. Haematologica, 2017, 102, e443-e446.	3.5	11
117	Trisomy 4 as the sole karyotypic anomaly in acute biphenotypic leukemia with B lineage markers and in acute minimally differentiated myeloid leukemia (MO). Cancer Genetics and Cytogenetics, 1995, 80, 66-67.	1.0	9
118	Surface-antigen expression profiling of B cell chronic lymphocytic leukemia: from the signature of specific disease subsets to the identification of markers with prognostic relevance. Journal of Translational Medicine, 2006, 4, 11.	4.4	9
119	CD49d expression in chronic lymphocytic leukemia: a prognostic parameter and a therapeutic target. Future Oncology, 2008, 4, 355-358.	2.4	9
120	Molecular and clinical features of chronic lymphocytic leukemia with stereotyped B-cell receptors in a Ukrainian cohort. Leukemia and Lymphoma, 2010, 51, 822-838.	1.3	9
121	Extensive toxic epidermal necrolysis following brentuximab vedotin administration. Annals of Hematology, 2015, 94, 355-356.	1.8	9
122	Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: correlation with biologically-based risk stratification. Haematologica, 2017, 102, e352-e355.	3.5	9
123	Prognostic Value of Cytogenetics and Multidrug Resistance (MDR1) in Elderly Patients With Acute Myeloid Leukemia. Blood, 1998, 92, 695-697.	1.4	9
124	Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab. Leukemia, 2018, 32, 1869-1873.	7.2	8
125	Impaired nodal shrinkage and apoptosis define the independent adverse outcome of NOTCH1 mutated patients under ibrutinib therapy in chronic lymphocytic leukaemia. Haematologica, 2021, 106, 2345-2353.	3.5	8
126	Molecular characterization of Phâ€2+ hybrid acute leukemia. Leukemia Research, 1989, 13, 1061-1067.	0.8	7

#	ARTICLE	IF	CITATIONS
127	Simultaneous Occurrence of Monoclonal Gammopathy and Acute Secondary Leukemia with Overexpression of P-Glycoprotein. Tumori, 1992, 78, 403-406.	1.1	7
128	Recombinant Interferon γ 2a, Thymopentin and Low Doses of Cytosine Arabinoside for the Treatment of Myelodysplastic Syndromes: A Pilot Study. Leukemia and Lymphoma, 1995, 16, 335-342.	1.3	7
129	Positive selection of CD34+ cells by immunoadsorption: factors affecting the final yield and hematopoietic recovery in patients with hematological malignancies and solid tumors. Transfusion and Apheresis Science, 2002, 26, 103-110.	1.0	7
130	Complete regression of cutaneous lesions of refractory Ph+ ALL after 4 weeks of treatment with BMS-354825. Blood, 2006, 107, 4571-4572.	1.4	7
131	Evaluation of the prognostic relevance of α -selectin and ICAM1 expression in myelodysplastic syndromes. European Journal of Haematology, 2008, 80, 107-114.	2.2	7
132	Management of hematological malignancies in patients affected by renal failure. Expert Review of Anticancer Therapy, 2011, 11, 415-432.	2.4	7
133	Dismal Outcome of Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia after Azacitidine Failure in a Daily-Life Setting. Acta Haematologica, 2015, 133, 64-66.	1.4	7
134	Role of Human Leukocyte Interferon- γ in the Treatment of Patients With Polycythemia Vera. American Journal of the Medical Sciences, 1998, 315, 237-241.	1.1	7
135	Increased levels of circulating interleukin-6 in patients with newly diagnosed non-Hodgkin's lymphomas. American Journal of Hematology, 1994, 46, 160-161.	4.1	5
136	One Year of Clinical Experience in Postdilution Hemofiltration with Online Reinfusion of Regenerated Ultrafiltrate. Blood Purification, 2004, 22, 505-509.	1.8	5
137	Gelatinous Degeneration of the Bone Marrow: Two Case Reports Showing Different Hematological Features and Clinical Outcomes. Acta Haematologica, 2007, 118, 165-166.	1.4	5
138	Front-Line Therapy for Elderly Chronic Lymphocytic Leukemia Patients: Bendamustine Plus Rituximab or Chlorambucil Plus Rituximab? Real-Life Retrospective Multicenter Study in the Lazio Region. Frontiers in Oncology, 2020, 10, 848.	2.8	5
139	Role of immunochemotherapy in the treatment of chronic lymphocytic leukemia. Expert Review of Anticancer Therapy, 2006, 6, 1787-1800.	2.4	4
140	A Novel t(11;12)(q23â€“24;q24) in a Case of Minimally-Differentiated Acute Myeloid Leukemia (AML-M0). Cancer Genetics and Cytogenetics, 2000, 118, 76-79.	1.0	3
141	Activation-Induced Cytidine Deaminase and CD38 Expression in B-Cell Chronic Lymphocytic Leukemia. Clinical Lymphoma and Myeloma, 2005, 6, 251-252.	1.4	3
142	How would I manage a sample submitted for flow cytometry analysis for suspicious chronic lymphocytic leukaemia. Hematological Oncology, 2009, 27, 186-189.	1.7	3
143	<i>ARHGDI1</i> , a mutant <i>TP53</i> -associated Rho GTPase dissociation inhibitor, is overexpressed in gene expression profiles of <i>TP53</i> disrupted chronic lymphocytic leukaemia cells. British Journal of Haematology, 2013, 161, 596-599.	2.5	3
144	Unexplained severe Coombs-negative hemolytic anemia during treatment of refractory chronic lymphocytic leukemia with alemtuzumab. Annals of Hematology, 2014, 93, 863-865.	1.8	3

#	ARTICLE	IF	CITATIONS
145	Hodgkin lymphoma in a mutated ZAP-70 negative B-cell Chronic Lymphocytic Leukemia patient. Leukemia Research, 2008, 32, 363-365.	0.8	2
146	Leukocyte Alkaline Phosphatase Score in Plasma Cell Dyscrasias: Correlation with Disease Severity and Circulating Levels of Granulocyte-Colony Stimulating Factor. Leukemia and Lymphoma, 1995, 17, 479-483.	1.3	1
147	Bone Marrow Necrosis as a Terminal Complication of a Very Long-Lasting Polycythemia Vera. International Journal of Hematology, 2007, 86, 377-378.	1.6	1
148	IGHD3 fails to behave as unfavourable prognostic marker in chronic lymphocytic leukaemia. British Journal of Haematology, 2010, 149, 299-302.	2.5	1
149	Pure erythroid leukemia in advanced breast cancer. Blood Research, 2014, 49, 69.	1.3	1
150	Fulminant B Hepatitis in a Hepatitis B Surface Antigen-Negative Patient after Rituximab Therapy for B-CLL. Blood, 2005, 106, 5025-5025.	1.4	1
151	Immunotherapeutic Maintenance Strategy Prolongs Response Duration and Overall Survival Preventing Relapse in Chronic Lymphocytic Leukemia (CLL). Blood, 2011, 118, 3906-3906.	1.4	1
152	Vitamin D and non-Hodgkin lymphomas, trends from an Italian monocentric study. Panminerva Medica, 2021, 63, 547-549.	0.8	1
153	Automated Haematology Analysers in Acute and Chronic Leukaemias. Acta Haematologica, 1998, 100, 61-62.	1.4	0
154	B-cell chronic lymphocytic leukemia. , 0, , 786-792.		0
155	Rituximab single agent in age-related Epstein-Barr virus associated B cell disorder complicated by autoimmune anemia and pure red cell aplasia. Annals of Hematology, 2014, 93, 1611-1612.	1.8	0
156	Pyrrolo[1,2-B][1,2,5] benzodiazepines (PBDTs) Compounds Induce Apoptosis in Chronic Myeloid Leukaemia Cells from Patients at Onset, Imatinib and Second Generation TK Inhibitors (Dasatinib,) Tj ETQq0 0 0 rgBT4/Overlock 10 Tf 50		
157	Acute Zoster Pain (AZP) and Post-Herpetic Neuralgia (PHN) in the Course of Lymphoproliferative Disorders (LPD): Durable Pain Relief Provided by Oxycodone in Patients Unresponsive to Standard Therapy.. Blood, 2006, 108, 5500-5500.	1.4	0
158	A Molecular Model to Predict Durable Remission after First Line Fludarabine-Cyclophosphamide-Rituximab Treatment in Chronic Lymphocytic Leukemia. Blood, 2014, 124, 3300-3300.	1.4	0